AMAG Pharmaceuticals Company Profile (NASDAQ:AMAG)

About AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals logoAMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:AMAG
  • CUSIP: 00163U10
  • Web: www.amagpharma.com
Capitalization:
  • Market Cap: $653.59 million
  • Outstanding Shares: 35,045,000
Average Prices:
  • 50 Day Moving Avg: $18.26
  • 200 Day Moving Avg: $23.88
  • 52 Week Range: $16.00 - $36.83
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 8.63
  • P/E Growth: -0.10
Sales & Book Value:
  • Annual Revenue: $562.26 million
  • Price / Sales: 1.16
  • Book Value: $26.83 per share
  • Price / Book: 0.70
Profitability:
  • EBIDTA: $246.86 million
  • Net Margins: -5.61%
  • Return on Equity: 1.69%
  • Return on Assets: 0.63%
Debt:
  • Debt-to-Equity Ratio: 1.04%
  • Current Ratio: 2.24%
  • Quick Ratio: 2.12%
Misc:
  • Average Volume: 1.25 million shs.
  • Beta: 1
  • Short Ratio: 4.26
 

Frequently Asked Questions for AMAG Pharmaceuticals (NASDAQ:AMAG)

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) released its quarterly earnings data on Tuesday, May, 2nd. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.09 by $1.15. The company had revenue of $139.47 million for the quarter, compared to analyst estimates of $150.32 million. AMAG Pharmaceuticals had a positive return on equity of 1.69% and a negative net margin of 5.61%. AMAG Pharmaceuticals's revenue for the quarter was up 27.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.22) earnings per share. View AMAG Pharmaceuticals' Earnings History.

When will AMAG Pharmaceuticals make its next earnings announcement?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, August, 7th 2017. View Earnings Estimates for AMAG Pharmaceuticals.

Where is AMAG Pharmaceuticals' stock going? Where will AMAG Pharmaceuticals' stock price be in 2017?

10 analysts have issued 1 year price targets for AMAG Pharmaceuticals' stock. Their predictions range from $20.00 to $45.00. On average, they expect AMAG Pharmaceuticals' share price to reach $29.88 in the next year. View Analyst Ratings for AMAG Pharmaceuticals.

What are analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "AMAG disclosed that the Makena auto-injector sNDA has been accepted for review and that the FDA set a PDUFA date of February 14, 2018." (6/26/2017)
  • 2. Jefferies Group LLC analysts commented, "No surprise vs. pre-announced 4Q16 results on 1/9/17. Another acquisition of women's health product Intrarosa also fails to excite investors (following Rekynda on 1/9/17). Given ongoing concerns, near-term we view limited upside; medium/long-term share price recovery would likely be driven by timely approval/successful launch of Makena 3.0 & strong Intrarosa uptake providing confidence in its commercial potential, which may not be materialized until ~2018." (2/15/2017)
  • 3. Guggenheim analysts commented, "Despite near-term setbacks, we continue to believe patience will be rewarded for AMAG investors with a longer-term horizon. However we are lowering our price target to $28 from $42. Our PT reduction is driven by lowered expectations for Makena life cycle extension. We believe Makena Sub-Q will face a challenging reimbursement environment, if approved, given the pain and Cmax PK data released this morning and expect generics to capture the majority of the market from '18+. Longer term stock price appreciation could be driven by Feraheme label expansion, CBR durability, Business Development, and Rekynda keep us positive." (2/2/2017)
  • 4. According to Zacks Investment Research, "We are concerned about AMAG’s dependence on sales of Makena, which primarily drives the company’s top line. We are also concerned about the company’s iron replacement therapy, Feraheme, which faces patent challenge in the U.S. In addition, inclusion of a boxed warning in Feraheme’s label is concerning. Moreover, termination of the marketing agreement with Takeda is a major setback for the company. Stiff competition and generic threats remain a woe as well. Estimates are stable ahead the company’s Q4 release. The company has recorded an average negative earnings surprise over the four trailing quarters. However, AMAG’s shares have outperformed the Medical-Biomedical/Genetics industry in the past one year." (1/9/2017)

Who are some of AMAG Pharmaceuticals' key competitors?

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the folowing people:

  • Gino Santini, Independent Chairman of the Board
  • William K. Heiden, President, Chief Executive Officer, Director
  • Edward Myles CPA, Chief Financial Officer, Senior Vice President - Finance, Treasurer
  • Nathan McBride, Senior Vice President - Innovation Architects, Chief Information Officer
  • Joseph D. Vittiglio, Senior Vice President - Legal Affairs, Technical Operations and Quality, General Counsel, Secretary
  • Tony Casciano, Senior Vice President of Sales and Marketing - Hematology and Oncology business
  • Paul Williams, Senior Vice President - Sales and Marketing, Women’s Health
  • Elizabeth Bolgiano, Senior Vice President of Human Resources
  • Julie Krop M.D., Chief Medical Officer and Senior Vice President - Clinical Development and Regulatory Affairs
  • Scott T. McMillan Ph.D., Senior Vice President - Quality and Technical Operations

Who owns AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (0.00%), Palo Alto Investors LLC (9.54%), Vanguard Group Inc. (0.00%), State Street Corp (7.20%), CAMBER CAPITAL MANAGEMENT LLC (7.13%) and CAMBER CAPITAL MANAGEMENT LLC (4.85%). Company insiders that own AMAG Pharmaceuticals stock include John A Fallon, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals.

Who sold AMAG Pharmaceuticals stock? Who is selling AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Ameriprise Financial Inc., Janus Capital Management LLC, Bank of America Corp DE, Schwab Charles Investment Management Inc., Falcon Point Capital LLC, Systematic Financial Management LP and Alliancebernstein L.P.. View Insider Buying and Selling for AMAG Pharmaceuticals.

Who bought AMAG Pharmaceuticals stock? Who is buying AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Acadian Asset Management LLC, State Street Corp, Dimensional Fund Advisors LP, Perceptive Advisors LLC, LSV Asset Management, Goldman Sachs Group Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for AMAG Pharmaceuticals.

How do I buy AMAG Pharmaceuticals stock?

Shares of AMAG Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG Pharmaceuticals stock can currently be purchased for approximately $18.65.


MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  386
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AMAG Pharmaceuticals (NASDAQ:AMAG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.10)
Consensus Price Target: $29.88 (60.19% upside)

Analysts' Ratings History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/26/2017Cantor FitzgeraldReiterated RatingHold$23.00MediumView Rating Details
6/1/2017Barclays PLCReiterated RatingEqual Weight$25.00 -> $20.00LowView Rating Details
5/3/2017Jefferies Group LLCReiterated RatingBuy$40.00 -> $34.00HighView Rating Details
2/3/2017Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
2/2/2017GuggenheimLower Price TargetBuy$42.00 -> $28.00N/AView Rating Details
1/31/2017J P Morgan Chase & CoSet Price TargetHold$24.00N/AView Rating Details
1/11/2017Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
1/10/2017Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market Perform$39.00 -> $25.00N/AView Rating Details
1/9/2017Raymond James Financial, Inc.Reiterated RatingMarket Perform -> UnderperformN/AView Rating Details
5/9/2016Deutsche Bank AGLower Price TargetHold$42.00 -> $35.00N/AView Rating Details
3/28/2016Robert W. BairdLower Price TargetOutperform$26.00 -> $25.00N/AView Rating Details
3/28/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralN/AView Rating Details
1/28/2016Northland SecuritiesInitiated CoverageOutperform$40.00N/AView Rating Details
(Data available from 6/29/2015 forward)

Earnings

Earnings History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Earnings by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Earnings History by Quarter for AMAG Pharmaceuticals (NASDAQ AMAG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017        
5/2/2017Q1 2017$0.09($1.06)$150.32 million$139.47 millionViewListenView Earnings Details
2/14/2017Q416$0.24($0.31)$155.12 million$151.60 millionViewListenView Earnings Details
11/3/2016Q316$1.50$1.78$141.65 million$143.80 millionViewListenView Earnings Details
8/9/2016Q216$1.20$1.45$128.52 million$127.40 millionViewListenView Earnings Details
5/3/2016Q116$1.11$0.94$124.83 million$117.60 millionViewListenView Earnings Details
2/17/2016Q415$1.16$1.12$120.13 million$108.70 millionViewListenView Earnings Details
11/3/2015Q315$1.21($0.62)$113.88 million$103.50 millionViewListenView Earnings Details
7/23/2015Q215$0.75$1.12$94.05 million$123.90 millionViewListenView Earnings Details
5/5/2015Q115$1.04$1.11$84.66 million$89.50 millionViewListenView Earnings Details
10/30/2014Q314($0.08)$0.06$26.30 million$25.50 millionViewListenView Earnings Details
7/29/2014Q214($0.09)($0.07)$23.40 million$24.80 millionViewListenView Earnings Details
4/24/2014Q1($0.07)($0.33)$22.73 million$20.80 millionViewListenView Earnings Details
2/6/2014Q4($0.10)($0.17)$21.01 million$21.70 millionViewListenView Earnings Details
10/17/2013Q313($0.12)($0.01)$20.37 million$21.60 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.17)($0.09)$18.51 million$19.60 millionViewListenView Earnings Details
4/23/2013Q1 2013($0.20)($0.18)$17.99 million$17.90 millionViewListenView Earnings Details
3/1/2013Q4 2012($0.06)($0.17)$22.54 million$21.14 millionViewN/AView Earnings Details
11/1/2012Q312($0.26)($0.19)$20.43 million$17.70 millionViewN/AView Earnings Details
7/26/2012($0.39)$0.16ViewN/AView Earnings Details
5/1/2012($0.63)($0.58)ViewN/AView Earnings Details
3/5/2012($1.09)($0.87)ViewN/AView Earnings Details
11/4/2011($0.98)($0.78)ViewN/AView Earnings Details
5/3/2011($0.99)($1.05)ViewN/AView Earnings Details
2/25/2011($1.04)($0.94)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)
2017 EPS Consensus Estimate: $0.53
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($1.05)($1.05)($1.05)
Q2 20171$0.58$0.58$0.58
Q3 20171$0.43$0.43$0.43
Q4 20171$0.57$0.57$0.57
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AMAG Pharmaceuticals (NASDAQ:AMAG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Insider Ownership Percentage: 3.80%
Insider Trades by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Insider Trades by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/1/2017Julie KropSVPSell1,891$24.45$46,234.95View SEC Filing  
10/20/2016Julie KropSVPSell4,938$24.80$122,462.40View SEC Filing  
11/10/2015John A FallonDirectorBuy3,230$31.20$100,776.00View SEC Filing  
10/1/2015William K HeidenCEOSell2,000$39.69$79,380.00View SEC Filing  
9/1/2015William K HeidenCEOSell2,000$61.19$122,380.00View SEC Filing  
7/15/2015William K HeidenCEOSell20,000$75.00$1,500,000.00View SEC Filing  
6/15/2015Scott A HolmesSVPSell7,580$66.63$505,055.40View SEC Filing  
6/5/2015William K HeidenCEOSell66,875$69.90$4,674,562.50View SEC Filing  
6/4/2015Frank E ThomasCOOSell20,000$69.47$1,389,400.00View SEC Filing  
6/3/2015Scott A HolmesSVPSell22,516$68.88$1,550,902.08View SEC Filing  
1/9/2015Adage Capital Partners Gp LlcMajor ShareholderSell1,250,000$46.49$58,112,500.00View SEC Filing  
1/9/2014Christopher WhiteInsiderSell4,000$22.37$89,480.00View SEC Filing  
1/7/2014Christopher WhiteInsiderSell5,000$23.90$119,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for AMAG Pharmaceuticals (NASDAQ:AMAG)
Latest Headlines for AMAG Pharmaceuticals (NASDAQ:AMAG)
Source:
DateHeadline
baystreet.ca logoAMAG in Green (Barely) on FDA Nod
www.baystreet.ca - June 27 at 8:35 PM
streetinsider.com logoAMAG Pharma (AMAG) Reports US FDA Filing Acceptance of Supplemental New Drug Application for Makena ... - StreetInsider.com
www.streetinsider.com - June 26 at 11:27 PM
streetinsider.com logoPre-Open Movers 06/26: (STOR) (PTLA) (P) Higher; (NEOT) (MTNB) (GRUB) Lower (more...)
www.streetinsider.com - June 26 at 3:58 PM
reuters.com logoBRIEF-Amag reports U.S. FDA acceptance of supplemental new drug application for Makena
www.reuters.com - June 26 at 3:58 PM
finance.yahoo.com logoAMAG Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for Makena® (hydroxyprogesterone caproate injection) Subcutaneous Auto-Injector
finance.yahoo.com - June 26 at 3:58 PM
finance.yahoo.com logoCould An FDA Delay Snag This Biotech's Pre-Term Birth Drug?
finance.yahoo.com - June 26 at 3:58 PM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Earns Hold Rating from Cantor Fitzgerald
www.americanbankingnews.com - June 26 at 11:34 AM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Expected to Announce Quarterly Sales of $157.92 Million
www.americanbankingnews.com - June 25 at 7:52 AM
americanbankingnews.com logoZacks: Analysts Anticipate AMAG Pharmaceuticals, Inc. (AMAG) Will Post Earnings of -$0.58 Per Share
www.americanbankingnews.com - June 23 at 10:22 PM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - June 16 at 10:32 AM
seekingalpha.com logoAMAG Pharmaceuticals (AMAG) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 7 at 8:36 PM
nasdaq.com logoWhy Is AMAG Pharmaceuticals (AMAG) Down 15.6% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - June 3 at 3:30 PM
finance.yahoo.com logoWhy Is AMAG Pharmaceuticals (AMAG) Down 15.6% Since the Last Earnings Report?
finance.yahoo.com - June 2 at 4:37 PM
americanbankingnews.com logoAMAG Pharmaceuticals' (AMAG) "Equal Weight" Rating Reiterated at Barclays PLC
www.americanbankingnews.com - June 1 at 7:28 PM
streetinsider.com logoAMAG Pharma (AMAG) Confirms 1st Patient Enrolled in Phase 2b ... - StreetInsider.com
www.streetinsider.com - June 1 at 3:43 PM
finance.yahoo.com logoAMAG Announces First Patient Enrolled in Phase 2b/3a Digoxin Immune Fab Study Conducted by Velo Bio
finance.yahoo.com - June 1 at 3:43 PM
americanbankingnews.com logo$157.92 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
www.americanbankingnews.com - June 1 at 10:10 AM
globenewswire.com logoAMAG Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - May 31 at 10:28 AM
americanbankingnews.com logoZacks: Analysts Expect AMAG Pharmaceuticals, Inc. (AMAG) to Post -$0.58 Earnings Per Share
www.americanbankingnews.com - May 30 at 6:18 PM
americanbankingnews.com logoLeerink Swann Comments on AMAG Pharmaceuticals, Inc.'s FY2018 Earnings (AMAG)
www.americanbankingnews.com - May 29 at 8:24 AM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 22 at 10:29 AM
nasdaq.com logoAMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs - Nasdaq
www.nasdaq.com - May 16 at 3:32 PM
finance.yahoo.com logoAMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs
finance.yahoo.com - May 16 at 3:32 PM
finance.yahoo.com logoAMAG Pharmaceuticals Appoints Helen Milton, Ph.D. as Vice President of Regulatory Affairs
finance.yahoo.com - May 16 at 3:32 PM
reuters.com logoBRIEF-Camber Capital Management LLC reports 7.13 pct passive stake in AMAG Pharmaceuticals
www.reuters.com - May 15 at 3:27 PM
globenewswire.com logoAMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy - GlobeNewswire (press release)
globenewswire.com - May 15 at 3:27 PM
finance.yahoo.com logoBear of the Day: AMAG Pharmaceuticals (AMAG)
finance.yahoo.com - May 15 at 3:27 PM
finance.yahoo.com logoBear of the Day: AMAG Pharmaceuticals (AMAG)
finance.yahoo.com - May 15 at 3:27 PM
finance.yahoo.com logoAMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy
finance.yahoo.com - May 15 at 3:27 PM
finance.yahoo.com logoAMAG Pharmaceuticals Completes Financing Transactions in Support of Future Growth Strategy
finance.yahoo.com - May 15 at 3:27 PM
finance.yahoo.com logoAlpha & Omega Semiconductor, AMAG Pharmaceuticals and Trade Desk highlighted as Zacks Bull and Bear of the Day
finance.yahoo.com - May 15 at 3:27 PM
finance.yahoo.com logoAlpha & Omega Semiconductor, AMAG Pharmaceuticals and Trade Desk highlighted as Zacks Bull and Bear of the Day
finance.yahoo.com - May 15 at 3:27 PM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - May 13 at 3:22 PM
finance.yahoo.com logoAMAG Pharmaceuticals, Inc. -- Moody's upgrades AMAG's sr. notes to Ba3; affirms B2 CFR
finance.yahoo.com - May 12 at 4:02 PM
nasdaq.com logoAMAG Pharmaceuticals to Host Analyst Day on May 24th in New ... - Nasdaq
www.nasdaq.com - May 11 at 1:42 AM
globenewswire.com logoAMAG Pharmaceuticals to Host Analyst Day on May 24th in New York - GlobeNewswire (press release)
globenewswire.com - May 10 at 3:38 PM
zacks.com logoWhat Makes AMAG Pharmaceuticals (AMAG) a Strong Sell?
www.zacks.com - May 10 at 9:24 AM
finance.yahoo.com logoAMAG Pharmaceuticals to Host Analyst Day on May 24th in New York
finance.yahoo.com - May 10 at 9:24 AM
americanbankingnews.com logoTheStreet Lowers AMAG Pharmaceuticals, Inc. (AMAG) to D+
www.americanbankingnews.com - May 9 at 3:50 PM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Earns Hold Rating from Barclays PLC
www.americanbankingnews.com - May 7 at 9:26 AM
streetinsider.com logoAMAG Pharma (AMAG) Prices Offering of $300M 3.25% Convertible Senior Notes Due 2022
www.streetinsider.com - May 6 at 1:32 AM
reuters.com logoBRIEF-Amag Pharmaceuticals Inc says increased size of offering to $300 mln
www.reuters.com - May 6 at 1:32 AM
finance.yahoo.com logoAMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 6 at 1:32 AM
finance.yahoo.com logoETFs with exposure to AMAG Pharmaceuticals, Inc. : May 5, 2017
finance.yahoo.com - May 5 at 8:30 PM
streetinsider.com logoForm FWP AMAG PHARMACEUTICALS Filed by: AMAG PHARMACEUTICALS INC. - StreetInsider.com
www.streetinsider.com - May 5 at 3:30 PM
reuters.com logoBRIEF-Amag Pharmaceuticals Inc says increased size of offering to $300 mln - Reuters
www.reuters.com - May 5 at 3:30 PM
americanbankingnews.com logo$0.09 Earnings Per Share Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
www.americanbankingnews.com - May 4 at 10:50 PM
finance.yahoo.com logoAMAG Pharmaceuticals, Inc. -- Moody's: AMAG's proposed refinancing credit positive
finance.yahoo.com - May 4 at 8:31 PM
americanbankingnews.com logoAMAG Pharmaceuticals, Inc. (AMAG) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - May 3 at 9:52 PM
nasdaq.com logoAMAG Pharma (AMAG) Incurs Loss in Q1, Revenues Rise Y/Y - Nasdaq
www.nasdaq.com - May 3 at 8:34 PM

Social

Chart

AMAG Pharmaceuticals (AMAG) Chart for Thursday, June, 29, 2017

This page was last updated on 6/29/2017 by MarketBeat.com Staff